Serological response to SARS‐CoV‐2 vaccination in patients with immunobullous diseases
Author:
Affiliation:
1. Department of Dermatology, Keck School of Medicine University of Southern California Los Angeles California USA
2. Department of Molecular Biology, Faculty of Biology University of Gdańsk Gdańsk Poland
Publisher
Wiley
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/jvc2.490
Reference7 articles.
1. The WHO has declared the end of pandemic phase of COVID‐19: way to come back in the normal life;Sarker R;Health Sci Rep,2023
2. Updated international expert recommendations for the management of autoimmune bullous diseases during the COVID‐19 pandemic;Kasperkiewicz M;J Eur Acad Dermatol Venereol,2021
3. Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS‐CoV‐2 vaccination in patients with rheumatic diseases;Spiera R;Ann Rheum Dis,2021
4. Anti‐spike protein to determine SARS‐CoV‐2 antibody levels: is there a specific threshold conferring protection in immunocompromised patients?;Halfon P;PLoS One,2023
5. Rituximab in immunobullous disorders during the COVID‐19 pandemic: A systematic review of observational studies;Kasperkiewicz M;J Eur Acad Dermatol Venereol,2023
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3